We've found
						161,353
						 archived clinical trials in
						Cancer
					
				We've found
						161,353
						 archived clinical trials in
						Cancer
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials
		    
			
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
	
	Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
	
Updated: 12/31/1969
  
  
  	  A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
		Status: Enrolling	
	Updated: 12/31/1969
Click here to add this to my saved trials